Ultragenyx is trading at $14.45 (-45.53%) in pre-market after its Phase 3 Aspire study of apazunersen failed to meet primary and key secondary endpoints.
- The trial found no efficacy difference versus control on cognitive scores or the multidomain responder measure.
- The company will evaluate whether to continue the Angelman syndrome program, driving the sharp overnight selloff.